South San Francisco, CA December 19, 2023 Press Release FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results If approved, Xolair would be the…
South San Francisco, CA December 14, 2023 Press Release Ashley Magargee has been appointed to the role of Chief Executive Officer of Genentech, a member of the Roche Group, effective January 1, 2024. In addition to her role as Head…
South San Francisco, CA December 4, 2023 Press Release Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation Phase III (INAVO120) results shows that inavolisib in combination…
South San Francisco, CA November 20, 2023 by Peter Feng, SSFUSD In honor of National STEM Day on November 8, the South San Francisco Unified School District (SSFUSD) celebrated its elementary school teachers for their efforts in implementing Twig…
South San Francisco, CA October 24, 2023 Submitted by Christina Fernandez, MPA | (she/her/hers) Deputy City Manager | Chief Sustainability Officer The City of South San Francisco will celebrate the grand opening of the new Library | Parks & Recreation…
South San Francisco, CA October 11, 2023 Press Release Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based…
South San Francisco, CA October 4, 2023 Press Release Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment RAINBOWFISH study met its primary endpoint with 80% of…
South San Francisco, CA October 2, 2023 Press Release Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous…
South San Francisco, CA September 30, 2023 South San Francisco Chamber of Commerce Genentech Goes to Town – Celebrating 30 Remarkable Years Our longstanding partnership with Genentech reaches a significant milestone this year—the 30th anniversary of ‘Genentech Goes to Town.’…
South San Francisco, CA September 6, 2023 Press Release Acceptance based on the Phase III COMMODORE 2 study, which demonstrated crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal hemoglobinuria (PNH) If approved, crovalimab will be the first…